There was a nonsignificant trend towards improved survival with Kaplan-Meier estimates of mortality by 14 days of 7.1% and 11.9% in the remdesivir and placebo groups, respectively.
1
—
—
There was a nonsignificant trend towards improved survival with Kaplan-Meier estimates of mortality by 14 days of 7.1% and 11.9% in the remdesivir and placebo groups, respectively.